中国临床医学2026，Vol.33Issue(2)：321-329,9.DOI:10.12025/j.issn.1008-6358.2025.20251534
前列腺癌177Lu-PSMA-617放射配体疗法研发历程、药物特性及临床应用
Development,pharmacological properties and clinical applications of 177Lu-PSMA-617 radioligand therapy in prostate cancer
吕靖 1刘国兵 1石洪成1
作者信息
- 1. 复旦大学附属中山医院核医学科,上海 200032
- 折叠
摘要
Abstract
Lutetium-177(177Lu)-prostate specific membrane antigen(PSMA)-617 is a small-molecule radioligand therapy(RLT)drug targeting PSMA.By selectively delivering the β-radiation emitted by 177Lu to PSMA-positive prostate cancer cells,it induces tumor cell death.The agent has been approved in multiple nations and regions for the treatment of PSMA-positive metastatic castration-resistant prostate cancer,thereby expanding therapeutic options for this patient population.This review outlines the development,pharmacological properties,and current clinical applications of 177Lu-PSMA-617,aiming to provide a theoretical basis for the clinical practice of RLT in prostate cancer treatment.关键词
前列腺癌/放射配体疗法/前列腺特异性膜抗原/镥-177/177Lu-PSMA-617Key words
prostate cancer/radioligand therapy/prostate specific membrane antigen/lutetium-177/177Lu-PSMA-617分类
医药卫生引用本文复制引用
吕靖,刘国兵,石洪成..前列腺癌177Lu-PSMA-617放射配体疗法研发历程、药物特性及临床应用[J].中国临床医学,2026,33(2):321-329,9.
